News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Udhayvir Grewal: Do you consider anti-EGFR moAbs in HER2+, RAS wild-type colorectal cancer?
Udhayvir Grewal/X
Apr 16, 2025, 20:16

Udhayvir Grewal: Do you consider anti-EGFR moAbs in HER2+, RAS wild-type colorectal cancer?

Udhayvir Grewal, Resident Physician at Ochsner LSU Health Shreveport Academy medical centre, shared a post on X:

“Do you consider anti-EGFR moAbs (Cetuximab or Panitumumab) in HER2+, RAS wild-type colorectal cancer? Some preclinical data suggest that there is some degree of primary resistance to anti-EGFR therapy in HER2+ CRC (mediated by downstream activation of ERK/2 pathway).
This was also demonstrated by a large retrospective analysis (lower ORR, higher risk of progression, similar OS).”

“Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer”

Authors: Vincenzo Sforza, Erika Martinelli , Fortunato Ciardiello, Valentina Gambardella, Stefania Napolitano, Giulia Martini, Carminia Della Corte, Claudia Cardone, Marianna L Ferrara, Alfonso Reginelli, Giuseppina Liguori, Giulio Belli, Teresa Troiani

Udhayvir Grewal: Do you consider anti-EGFR moAbs in HER2+, RAS wild-type colorectal cancer?

“Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes”

Authors: Tanios S Bekaii-Saab, Krzysztof Lach, Ling-I Hsu, Muriel Siadak, Mike Stecher, James Ward, Rachel Beckerman, John H Strickler

Udhayvir Grewal: Do you consider anti-EGFR moAbs in HER2+, RAS wild-type colorectal cancer?

Alfonso Reginelli cancer Carminia Della Corte Claudia Cardone colorectal cancer Erika Martinelli Fortunato Ciardiello Giulia Martini Giulio Belli Giuseppina Liguori James Ward John H Strickler Krzysztof Lach Ling-I Hsu Marianna L Ferrara Mike Stecher Muriel Siadak OncoDaily Oncology Rachel Beckerman Stefania Napolitano Tanios S Bekaii-Saab Teresa Troiani Udhayvir Grewal Valentina Gambardella Vincenzo Sforza
Special Coverage
Blog
Apr 20, 2025, 12:54
The invitation to the 6th Annual Meeting in Budapest is waiting for you - SIOP Europe
Blog
Apr 20, 2025, 12:40
Small Cell SMASHERS series highlights the latest discoveries and breakthroughs for SCLC - LUNGevity Foundation
Science
Apr 20, 2025, 12:33
Naveen Pemmaraju: Idarubicin and Cytarabine for patients with relapsed and/or refractory AML
Blog
Apr 20, 2025, 12:23
Proud to have over 70 Cardio-Oncology Centers of Excellence around the world - International Cardio-Oncology Society
Blog
Apr 20, 2025, 12:18
Every child deserves a safe, welcoming space during cancer treatment - Childhood Cancer International
Blog
Apr 20, 2025, 12:15
Hidehito HORINOUCHI: Honored to have been nominated for IASLC 2025 Board of Directors Election
Societies
Apr 20, 2025, 12:10
Where to Study to Become ASCO President: 2025 Institutional Rankings
Blog
Apr 20, 2025, 12:03
NCODA - HealthWell Foundation has opened a fund to support individuals living with NETs
Blog
Apr 20, 2025, 12:02
Himil Mahadevia: Humbled to receive the 2025 Conquer Cancer Merit Award for our study on CART outcomes
Blog
Apr 20, 2025, 11:57
David Zaas: Inspiring day with the team at Atrium Health Wake Forest Baptist Wilkes Medical Center
Blog
Apr 20, 2025, 11:55
ESMO Fellowship applications are now open!
Blog
Apr 20, 2025, 11:55
Petros Grivas: Support to our fundraising effort for bladder cancer